Access to the Rigaku’s Electron Diffraction Technology without the Capital Outlay

With convenient and economical access to Rigaku’s state-of-the-art electron diffraction capabilities and applications experts, crystallization trials on samples smaller than 1 micron no longer need to delay your structural analysis programs.

Image credit: Rigaku

Frankfurt, Germany, May 24 -  Rigaku is excited to announce that they are providing access to their state-of-the-art electron diffraction technology for crystallography projects in pharmaceuticals, organic and inorganic chemistry, materials science and even mineralogy. Researchers from industry and academia will now be able utilize the world’s first turnkey electron diffractometer, the Rigaku XtaLAB Synergy-ED, without the expense of having to buy one. The new program provides access to instrumentation and software–as well as in-house expertise–to assist with your projects.

Electron diffraction is a rapidly emerging single-crystal technique for elucidating atomic structures of pharmaceuticals, catalysts, biominerals, nanomaterials and many other materials, with crystal grain sizes below 1 µm. It requires only minute amounts of sample material, and is compatible with extremely radiation-sensitive crystals. For such systems, electron diffraction goes far beyond the limits of X-ray diffraction, and has been shown to succeed where even synchrotrons can’t.

Rigaku will provide a comprehensive crystal structure determination service with scientific support from experienced application scientists that provides full access to everything you could possibly need, including the strictest confidentiality. Besides a refined atomic model, clients will receive all raw data generated and full access to all the software required for data processing and solution. Rigaku’s widely trusted and user-friendly CrysAlisPro and AutoChem packages will be immediately familiar to users of Rigaku’s single-crystal diffractometers, providing an effortless transition.

Dr. Mark Benson, General Manager of Global Sales and Marketing for Single Crystal  said, “We are extremely proud of the technology we have developed and understand that it has extraordinary potential for the scientific community. We also appreciate that not everyone will be able to afford to have their own Rigaku XtaLAB Synergy-ED electron diffractometer. For these reasons, we are making our technology more widely available, which will suit pharmaceutical and chemical research companies with small projects or immediate needs, or even small start-ups on tight budgets needing answers that only electron diffraction can provide.”

Dr. Robert Bücker, Product Manager for Electron Diffraction, added, “We have run pilot trials with pharmaceutical companies and university laboratories already. They have been extremely pleased with the service we have provided, with regards to both results and rapid turnaround time. Based on this, I anticipate this service becoming very popular and I urge anyone interested to come talk to us soon so we can get your project queued up.”

For more information or to contact Rigaku to discuss your specific project, please visit Rigaku.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Rigaku Corporation. (2022, May 25). Access to the Rigaku’s Electron Diffraction Technology without the Capital Outlay. AZoLifeSciences. Retrieved on July 01, 2022 from https://www.azolifesciences.com/news/20220525/Access-to-the-Rigakue28099s-Electron-Diffraction-Technology-without-the-Capital-Outlay.aspx.

  • MLA

    Rigaku Corporation. "Access to the Rigaku’s Electron Diffraction Technology without the Capital Outlay". AZoLifeSciences. 01 July 2022. <https://www.azolifesciences.com/news/20220525/Access-to-the-Rigakue28099s-Electron-Diffraction-Technology-without-the-Capital-Outlay.aspx>.

  • Chicago

    Rigaku Corporation. "Access to the Rigaku’s Electron Diffraction Technology without the Capital Outlay". AZoLifeSciences. https://www.azolifesciences.com/news/20220525/Access-to-the-Rigakue28099s-Electron-Diffraction-Technology-without-the-Capital-Outlay.aspx. (accessed July 01, 2022).

  • Harvard

    Rigaku Corporation. 2022. Access to the Rigaku’s Electron Diffraction Technology without the Capital Outlay. AZoLifeSciences, viewed 01 July 2022, https://www.azolifesciences.com/news/20220525/Access-to-the-Rigakue28099s-Electron-Diffraction-Technology-without-the-Capital-Outlay.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post